The Street’s Key Stock Analysts Research Reports

$BIIB, $BSX, $CLOV, $GM, $GERN, $SHOP

Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of The Street’s Key analysts outlook for Key issues for Thursday as follows

Biogen Inc. (NASDAQ:BIIB) was maintained as Market Perform and the price target was lowered to 318 from 337 at RBC Capital Markets. The firm expects no growth in its stock price with its MS drug revenues at potential, with flat or even lower sales trends ahead.

Boston Scientific Corp. (NYSE:BSX): Analysts reiterated BSX as Buy and the price target was raised to 45 from 43 at Argus. The consensus target price is 42.22 and the 52-wk trading range is 25.93 – 40.33.

Clovis Oncology Inc. (NASDAQ:CLOV) was started with a Buy rating and assigned a 40 price target at H.C. Wainwright. This stock trades a 52-wk range of 11.50 – 65.24, and its consensus target price is at 28.10.

General Motors Co. (NYSE:GM) was started with a Buy rating at Seaport Global. GM trsdes in a 52-wk range of 30.56 – 45.00 with an analysts consensus target price of 45.45.

Geron Corp. (NASDAQ:GERN) was started with a Buy rating and assigned a 4 target price at BTIG Research. The stock trades in a 52-wk range of 0.95 – 6.99.

Shopify Inc. (NYSE:SHOP) Wedbush Securities reiterated its Outperform rating and 200 price target, noting that Shopify is well positioned to keep gaining its share of e-commerce wallets over time and to capture more merchants across the entire spectrum of size from aspirational to established companies to enterprise level.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :  
CONNECT WITH